# Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

> **NCT05997615** · PHASE1 · RECRUITING · sponsor: **Vir Biotechnology, Inc.** · enrollment: 390 (estimated)

## Conditions studied

- Hormone-refractory Prostate Cancer

## Interventions

- **DRUG:** VIR-5500
- **COMBINATION_PRODUCT:** Enzalutamide
- **COMBINATION_PRODUCT:** Darolutamide

## Key facts

- **NCT ID:** NCT05997615
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-10
- **Primary completion:** 2027-09-29
- **Final completion:** 2027-09-29
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05997615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05997615, "Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05997615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*